{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:58:03Z","timestamp":1772078283432,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T00:00:00Z","timestamp":1402099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"NIAID, NIH","award":["HHSN266200700002C\/N01-AI-70002"],"award-info":[{"award-number":["HHSN266200700002C\/N01-AI-70002"]}]},{"name":"AIDS Research Institute at UCSF"},{"name":"Harvey V. Berneking Living Trust"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.virol.2014.05.036","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T00:31:17Z","timestamp":1403656277000},"page":"115-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice"],"prefix":"10.1016","volume":"462-463","author":[{"given":"Cheryl A.","family":"Stoddart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofiya A.","family":"Galkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pheroze","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Kosikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Maidji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ukina R.","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Witold","family":"Cieplak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Wrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Ying","family":"Chan-Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2014.05.036_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/jvi.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib2","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1128\/JVI.73.8.6361-6369.1999","article-title":"Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy","volume":"73","author":"Amado","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib3","first-page":"56","article-title":"Consistent production of genetically stable mammalian cell lines","volume":"25","author":"Bleck","year":"2012","journal-title":"BioPharm Int."},{"key":"10.1016\/j.virol.2014.05.036_bib4","doi-asserted-by":"crossref","first-page":"9998","DOI":"10.1128\/JVI.05045-11","article-title":"Analysis of a clonal lineage of HIV-1 envelope V2\/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors","volume":"85","author":"Bonsignori","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib5","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1073\/pnas.1103012108","article-title":"Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody","volume":"108","author":"Burton","year":"2011","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2014.05.036_bib6","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1128\/jvi.64.10.4735-4742.1990","article-title":"Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation","volume":"64","author":"Cann","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/cei.12180","article-title":"Human immune system development and survival of non-obese diabetic (NOD)-scid IL2r\u03b3(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells","volume":"174","author":"Covassin","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.virol.2014.05.036_bib8","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1128\/JVI.00411-11","article-title":"Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16","volume":"85","author":"Davenport","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1084\/jem.20130221","article-title":"Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies","volume":"210","author":"Diskin","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2014.05.036_bib10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.1213782","article-title":"Increasing the potency and breadth of an HIV antibody by using structure-based rational design","volume":"334","author":"Diskin","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.virol.2014.05.036_bib11","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1084\/jem.190.12.1857","article-title":"Experimental transmission of Kaposi\u2019s sarcoma-associated herpesvirus (KSHV\/HHV-8) to SCID-hu Thy\/Liv mice","volume":"190","author":"Dittmer","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2014.05.036_bib12","doi-asserted-by":"crossref","first-page":"10510","DOI":"10.1128\/JVI.00552-10","article-title":"Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16","volume":"84","author":"Doores","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib13","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1128\/JVI.06973-11","article-title":"PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4","volume":"86","author":"Falkowska","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib14","doi-asserted-by":"crossref","first-page":"e4505","DOI":"10.1371\/journal.pone.0004505","article-title":"International network for comparison of HIV neutralization assays: the NeutNet report","volume":"4","author":"Fenyo","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2014.05.036_bib15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm1297-1389","article-title":"Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1","volume":"3","author":"Gauduin","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2014.05.036_bib16","doi-asserted-by":"crossref","first-page":"e44664","DOI":"10.1371\/journal.pone.0044664","article-title":"Graft versus host disease in the bone marrow, liver and thymus humanized mouse model","volume":"7","author":"Greenblatt","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2014.05.036_bib17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/nar\/13.3.1015","article-title":"A novel strategy for constructing clustered point mutations","volume":"13","author":"Haltiner","year":"1985","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virol.2014.05.036_bib18","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nm.1974","article-title":"Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques","volume":"15","author":"Hessell","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2014.05.036_bib19","doi-asserted-by":"crossref","first-page":"e1000433","DOI":"10.1371\/journal.ppat.1000433","article-title":"Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers","volume":"5","author":"Hessell","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2014.05.036_bib20","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/JVI.01272-09","article-title":"Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L","volume":"84","author":"Hessell","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib21","doi-asserted-by":"crossref","first-page":"e36438","DOI":"10.1371\/journal.pone.0036438","article-title":"International network for comparison of HIV neutralization assays: the NeutNet report II","volume":"7","author":"Heyndrickx","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2014.05.036_bib22","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1315295110","article-title":"HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice","volume":"110","author":"Horwitz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2014.05.036_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.virol.2014.05.036_bib24","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.4049\/jimmunol.162.12.7555","article-title":"Induction of MHC class I expression on immature thymocytes in HIV-1-infected SCID-hu Thy\/Liv mice: evidence of indirect mechanisms","volume":"162","author":"Kovalev","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2014.05.036_bib25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.3646751","article-title":"Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms","volume":"236","author":"Koyanagi","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.virol.2014.05.036_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2005-11-4388","article-title":"Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus\/liver and CD34+ cell transplantation","volume":"108","author":"Lan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.virol.2014.05.036_bib27","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.virol.2014.05.036_bib28","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/JVI.06676-11","article-title":"Alpha interferon and HIV infection cause activation of human T cells in NSG-BLT mice","volume":"86","author":"Long","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib29","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1128\/JVI.73.5.4009-4018.1999","article-title":"Protection of Macaques against pathogenic simian\/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies","volume":"73","author":"Mascola","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"Mascola","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2014.05.036_bib31","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nature10696","article-title":"Structure of HIV-1 gp120 V1\/V2 domain with broadly neutralizing antibody PG9","volume":"480","author":"McLellan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.virol.2014.05.036_bib32","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/nm1431","article-title":"Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1","volume":"12","author":"Melkus","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2014.05.036_bib33","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2014.05.036_bib34","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1128\/jvi.68.6.4031-4034.1994","article-title":"Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS","volume":"68","author":"Muster","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib35","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1084\/jem.172.4.1055","article-title":"Long-term human hematopoiesis in the SCID-hu mouse","volume":"172","author":"Namikawa","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2014.05.036_bib36","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1128\/JVI.00966-10","article-title":"Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1","volume":"84","author":"Pancera","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib37","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1128\/JVI.75.17.8340-8347.2001","article-title":"Antibody protects macaques against vaginal challenge with a pathogenic R5 simian\/human immunodeficiency virus at serum levels giving complete neutralization in vitro","volume":"75","author":"Parren","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib38","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1073\/pnas.1004600107","article-title":"Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1","volume":"107","author":"Pejchal","year":"2010","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2014.05.036_bib39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1074-7613(00)80043-6","article-title":"Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo","volume":"10","author":"Poignard","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2014.05.036_bib40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1128\/AAC.40.3.755","article-title":"Use of standardized SCID-hu Thy\/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds","volume":"40","author":"Rabin","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2014.05.036_bib41","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection","volume":"100","author":"Richman","year":"2003","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2014.05.036_bib42","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1128\/jvi.68.8.4821-4828.1994","article-title":"Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1","volume":"68","author":"Roben","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib43","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jis183","article-title":"Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection","volume":"205","author":"Sagar","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2014.05.036_bib44","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.virol.2014.05.036_bib45","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1089\/08892220152741450","article-title":"A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1","volume":"17","author":"Stiegler","year":"2001","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.virol.2014.05.036_bib46","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1371\/journal.pone.0000655","article-title":"Validation of the SCID-hu Thy\/Liv mouse model with four classes of licensed antiretrovirals","volume":"2","author":"Stoddart","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2014.05.036_bib47","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/AAC.44.3.783-786.2000","article-title":"Antiviral activity of 2\u2032-deoxy-3\u2032-oxa-4\u2032-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy\/Liv mice","volume":"44","author":"Stoddart","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2014.05.036_bib48","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1128\/AAC.05015-11","article-title":"Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy\/Liv mice","volume":"56","author":"Stoddart","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2014.05.036_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/1074-7613(95)90076-4","article-title":"HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo","volume":"2","author":"Su","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2014.05.036_bib50","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/jvi.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1","volume":"70","author":"Trkola","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2014.05.036_bib51","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.virol.2014.05.036_bib52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.virol.2014.05.036_bib53","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.virol.2014.05.036_bib54","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.1207532","article-title":"Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing","volume":"333","author":"Wu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.virol.2014.05.036_bib55","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682214002591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682214002591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:27:28Z","timestamp":1758587248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682214002591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":55,"alternative-id":["S0042682214002591"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2014.05.036","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2014.05.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}